Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain

Inclusion Criteria: * Hospitalized patients with diagnosis of cancer * History of moderate to severe cancer related pain, defined as Numerical Rating Scale (NRS) pain score \>= 4/10 * Receiving no or only on as needed doses of opioids * Normal cognitive status, defined as a normal state of arousal and an absence of obvious clinical findings of confusion, memory deficits or concentration deficits or a Memorial Delirium Assessment Scale (MDAS) score of \< 13 * Ability to read and communicate in the English language * Written informed consent from patient Exclusion Criteria: * Contraindications to opioids, or history of opioid allergy * Inability to secure IV access * Known history or evidence of nonmedical opioid use (e.g. abuse, misuse, addiction) * Oxygen saturations \< 92% or respiratory rate \< 12 breaths/minute on initial assessment * Resting heart rate \> 120 on initial assessment * Systolic blood pressure \> 180 \< 90 mmHg or diastolic pressure \> 100 \< 60 mmHg on initial assessment * Patients receiving scheduled chronic opioid therapy (defined as the treatment of pain with opioids for \>= 7 days) * Moderate to severe renal insufficiency (defined as glomerular filtration rate \[GFR\] \< 60 ml/min/1.73 m\^2) * Hepatic insufficiency (defined as alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \> 3 times the highest normal value, or total bilirubin \> 1.5 times the highest normal value)